Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 55 points (-0.4%) at 14,948 as of Wednesday, Aug. 21, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 846 issues advancing vs. 2,101 declining with 78 unchanged. The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Sanofi ( SNY), down 2.1%, Novo Nordisk A/S ( NVO), down 0.8%, AstraZeneca ( AZN), down 0.7% and Novartis ( NVS), down 0.5%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Valeant Pharmaceuticals International is down $1.28 (-1.3%) to $100.25 on average volume. Thus far, 687,891 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $99.61-$101.61 after having opened the day at $101.42 as compared to the previous trading day's close of $101.53. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $33.6 billion and is part of the health care sector. Shares are up 69.9% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Valeant Pharmaceuticals International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.